| 產品編號 | bs-4312R-Gold |
| 英文名稱1 | Rabbit Anti-MYST1/KAT8/Gold Conjugated antibody |
| 中文名稱 | 膠體金標記的組蛋白乙酰轉移酶MOF抗體 |
| 別 名 | EC 2.3.1.48; Histone acetyltransferase KAT8; Histone acetyltransferase MYST1; hMOF; K(lysine) acetyltransferase 8; KAT 8; Lysine acetyltransferase 8; MOF; MOZ; MOZ, YBF2/SAS3, SAS2 and TIP60 protein 1; MYST 1; MYST histone acetyltransferase 1; myst protein 1; MYST-1; MYST1; MYST1_HUMAN; Ortholog of Drosophila males absent on the first (MOF); Probable histone acetyltransferase MYST1; SAS2 and TIP60 protein 1; SAS2; SAS3; TIP60 protein 1; YBF2; YBF2/SAS3. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 研究領域 | 腫瘤 細胞生物 表觀遺傳學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep, ) |
| 產品應用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 52kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MOF/KAT8/MYST1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產品介紹 |
background: Dosage compensation ensures that males with a single X chromosome and females with two X chromosomes have the same amount of most X-linked gene products. In Drosophila, this is acheived by enhancing the level of transcription of the X chromosome in males. Proteins such as maleless, male specific lethal 1, 2 and 3, and males absent on the first (MOF) form a dosage compensation complex (DCC) that is required for the twofold increase of transcription of the male X chromosome. The DCC is preferentially associated with many sites on the X chromosome in somatic cells of males. The binding of the DCC to the X chromosome is dependent upon histone 4 acetylation at lysine 16, which is accomplished by MOF. In mammals, MOF (also designated hMOF, MYST1, or MOZ) belongs to the MYST family of histone acetyl transferases which are characterized by a unique C2HC-type zinc finger close to their HAT domains. MOF utilizes the zinc finger domain to contact the globular part of the nucleosome as well as the histone H4 N-terminal tail substrate. The carboxy terminal domain of human MOF also has histone acetyltransferase activity directed against histones H3 and H2A, a characteristic shared with other MYST family histone acetyltransferases. Function: Histone acetyltransferase which may be involved in transcriptional activation. May influence the function of ATM. Subunit: Component of a multisubunit histone acetyltransferase complex (MSL) at least composed of the MOF/KAT8, MSL1/hampin, MSL2L1 and MSL3L1. Component of the NSL complex at least composed of MOF/KAT8, KANSL1, KANSL2, KANSL3, MCRS1, PHF20, OGT1/OGT, WDR5 and HCFC1. Component of some MLL1/MLL complex, at least composed of the core components MLL, ASH2L, HCFC1, WDR5 and RBBP5, as well as the facultative components BAP18, CHD8, E2F6, HSP70, INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, MOF/KAT8, PELP1, PHF20, PRP31, RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 and TEX10. Interacts with the chromodomain of MORF4L1/MRG15. Interacts with ATM through the chromodomain. Interacts with KANSL1; the interaction is direct. Subcellular Location: Nucleus. Chromosome. Post-translational modifications: Autoacetylation at Lys-274 is required for proper function. Similarity: Belongs to the MYST (SAS/MOZ) family. Contains 1 C2HC-type zinc finger. Contains 1 chromo domain. Database links: Entrez Gene: 84148 Human Omim: 609912 Human SwissProt: Q9H7Z6 Human Unigene: 533803 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
